Vietnam.vn - Nền tảng quảng bá Việt Nam

HIV drug named 'Breakthrough of the Year' 2024

Tạp chí Doanh NghiệpTạp chí Doanh Nghiệp30/12/2024


In December 2024, the American scientific journal Science honored lenacapavir - a new generation of injectable drugs used to treat HIV-infected patients as "Breakthrough of the Year". A large-scale study showed that the drug is up to 100% effective in preventing the disease of the century.

Lenacapavir, sold under the brand name Sunlenca, is a new class of antiviral drugs developed by the biopharmaceutical company Gilead Sciences. It works by blocking the formation of the capsid, the protein shell that surrounds the genetic material of the HIV virus and is responsible for protecting the virus's genome.

The US Food and Drug Administration (FDA) has approved lenacapavir to treat patients with multidrug-resistant HIV since 2022. A large-scale study conducted by Gilead Sciences on young women and adolescent girls in Africa in June showed that the drug is up to 100% effective in preventing the disease of the century.

HIV

Large-scale clinical trials have shown that lenacapavir is almost completely effective in preventing HIV infection. A study of more than 5,000 young African women found no cases of HIV infection after lenacapavir injection, a 100% effectiveness. Another trial of more than 2,000 people of different genders also recorded a prevention effectiveness of up to 99.9%.

Unlike current antiviral drugs that target viral enzymes, lenacapavir inhibits the HIV envelope protein (capsid). This protein forms a protective shell around the virus's genetic material, allowing it to enter human cells. Lenacapavir binds to the capsid, stiffening the shell, preventing the virus from entering cells and replicating.

This new mechanism of action not only provides high preventive efficacy but also opens up prospects for developing similar drugs to treat other viral diseases.

Many HIV/AIDS researchers hope that the drug developed by US biopharmaceutical company Gilead Sciences will have a dramatic effect in reducing global infection rates when used as pre-exposure prophylaxis (PrEP).

The goal is to start distributing lenacapavir in late 2025 or early 2026, said Hui Yang, director of supply operations at the Global Fund to Fight AIDS, Tuberculosis and Malaria. But there are still many steps to complete, including getting the injection approved by regulatory agencies such as the US Food and Drug Administration (FDA) and the World Health Organization (WHO), Yang said.

“We don’t want low- and middle-income countries to wait and be left behind,” Ms. Yang stressed, pointing to decades of inequality in the fight against HIV.

According to Intellectual Property



Source: https://doanhnghiepvn.vn/cong-nghe/thuoc-dieu-tri-hiv-duoc-vinh-danh-dot-pha-cua-nam-2024/20241230103024549

Comment (0)

No data
No data
3 islands in the Central region are likened to Maldives, attracting tourists in the summer
Watch the sparkling Quy Nhon coastal city of Gia Lai at night
Image of terraced fields in Phu Tho, gently sloping, bright and beautiful like mirrors before the planting season
Z121 Factory is ready for the International Fireworks Final Night
Famous travel magazine praises Son Doong cave as 'the most magnificent on the planet'
Mysterious cave attracts Western tourists, likened to 'Phong Nha cave' in Thanh Hoa
Discover the poetic beauty of Vinh Hy Bay
How is the most expensive tea in Hanoi, priced at over 10 million VND/kg, processed?
Taste of the river region
Beautiful sunrise over the seas of Vietnam

Heritage

Figure

Business

No videos available

News

Political System

Local

Product